Perspective Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

CATX$0.79-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(Dollars and shares in thousands, except for per-share amounts)

	Year Ended December 31,
	2025	2024
Grant revenue	$884	$1,454
Operating expenses:
Research and development	84,215	41,638
General and administrative	30,233	26,613
Goodwill impairment	-	24,062
Loss on disposal of property and equipment	-	27
Total operating expenses	114,448	92,340
Operating loss	(113,564)	(90,886)
Non-operating income (expense):
Interest income	8,114	10,515
Interest and other expense	(376)	(48)
Other income from a related party (Note 3)	1,400	-
Equity in loss of affiliate	(2)	(8)
Total non-operating income, net	9,136	10,459
Net loss from continuing operations	(104,428)	(80,427)
Net gain (loss) from discontinued operations	514	(949)
Net loss before deferred income tax benefit	(103,914)	(81,376)
Deferred income tax benefit	793	2,097
Net loss	$(103,121)	$(79,279)
Basic and diluted loss per share:
Loss from continuing operations	$(1.41)	$(1.22)
Gain (loss) from discontinued operations	0.01	(0.01)
Basic and diluted loss per share	$(1.40)	$(1.23)
Weighted average number of common shares used in computing net loss per share, basic and diluted:	73,813	64,425
Unrealized gain (loss) on available-for-sale securities	$161	$(51)
Comprehensive loss	$(102,960)	$(79,330)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.